Shandong Provincial Hospital
π¨π³China
- Country
- π¨π³China
- Ownership
- Private
- Established
- 2022-03-18
- Employees
- -
- Market Cap
- -
- Website
- http://www.sph.com.cn
Quality of Life and Psychosocial Status of Young-onset Patients With Rectal Cancer
Recruiting
- Conditions
- Rectal Cancer
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06216834
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
Clinicopathological Features and Molecular Typing of Invasive Fibroma of Abdominal Wall
Recruiting
- Conditions
- Aggressive Fibromatosis of Abdominal Wall (Disorder)
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06204198
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
Effectiveness of Detachment of the Breathing Circuit on the Rate of DLT Malposition After Postural Change
Not Applicable
Not yet recruiting
- Conditions
- Patient PositioningIntratracheal Intubation
- Interventions
- Behavioral: Disengage the breathing circuit
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 256
- Registration Number
- NCT06182371
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
Active, not recruiting
- Conditions
- Early Hepatocellular Carcinoma
- Interventions
- Procedure: MWA
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 334
- Registration Number
- NCT06096896
- Locations
- π¨π³
Shandong PH, Jinan, China
Endocrine Glucose & Lipids Metabolism and Brain Aging: a Longitudinal Study
Recruiting
- Conditions
- Brain Aging Related Conditions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 10000
- Registration Number
- NCT06066775
- Locations
- π¨π³
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Clinical Study of Umbilical Cord Blood Mononuclear Cell Therapy for the Treatment of Chronic Atrophic Gastritis
Not Applicable
Active, not recruiting
- Conditions
- Chronic Atrophic Gastritis
- Interventions
- Biological: Mononuclear cellsDrug: Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05808010
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 410
- Registration Number
- NCT05697055
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study
Recruiting
- Conditions
- Lymph Node MetastasisGastric Cancer Stage
- Interventions
- Diagnostic Test: coagulation-related factors
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 516
- Registration Number
- NCT05592925
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer
Completed
- Conditions
- Bladder Cancer
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05290623
- Locations
- π¨π³
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Phase 3
Recruiting
- Conditions
- Mantle Cell LymphomaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDiffuse Large B Cell LymphomaB-cell Non Hodgkin Lymphoma
- Interventions
- Drug: Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTXDrug: R-CHOP; R-DA-EPOCH; R-HD MTX
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT05164770
- Locations
- π¨π³
Department of Hematology, Shandong Provincial Hospital, Jinan, Shandong, China
Β© Copyright 2025. All Rights Reserved by MedPath